The unexploited potential of data systems tracking medicines utilization: an opportunity to improve access to oncology combination therapies
While most countries possess data systems that could serve as a foundation for tracking combination oncology therapies, these systems require optimization and proper implementation. Our core recommendation is for policymakers to explore the expansion and enhancement of data infrastructures.
Authors
- David Dodwell (ORCID: https://orcid.org/0000-0001-8787-4904)
- Lisa Pont (ORCID: https://orcid.org/0000-0002-8545-716X)
- Michael Hartevelt
- Caridad Pontes (ORCID: https://orcid.org/0000-0002-3274-6048)
- Steven Simoens (ORCID: https://orcid.org/0000-0002-9512-2005)
- Peter Lindgren (ORCID: https://orcid.org/0000-0002-8238-8189)
- Michele Pistollato
- Entela Xoxi (ORCID: https://orcid.org/0000-0003-0904-9225)
- Alexander Roediger (ORCID: https://orcid.org/0000-0001-8402-1797)
- Qinyi Wang (ORCID: https://orcid.org/0000-0001-9858-1170)
- Cornelia Wenger (ORCID: https://orcid.org/0000-0001-7889-9093)
- Éric Van Ganse (ORCID: https://orcid.org/0000-0002-7463-9187)
- Tim Wilsdon (ORCID: https://orcid.org/0000-0003-4365-7953)
- Brian Godman (ORCID: https://orcid.org/0000-0001-6539-6972)
- Antun Sablek
Institutions
- Université Claude Bernard Lyon 1 (FR)
- University of Technology Sydney (AU)
- Universitat Autònoma de Barcelona (ES)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Public Health Agency of Sweden (SE)
- University of Strathclyde (GB)
- Swiss National Park (CH)
- Sefako Makgatho Health Sciences University (ZA)
- Karolinska Institutet (SE)
- University of Oxford (GB)
- Charles River Laboratories (United Kingdom) (GB)
- Swedish Institute for Health Economics (SE)
- Karolinska Development (Sweden) (SE)
- University of the Sacred Heart (JP)
- KU Leuven (BE)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-08-20
- DOI
- https://doi.org/10.3389/fphar.2025.1532022
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Merck Sharp and Dohme